section name header

Pronunciation

soo-ma-TRIP-tan

Classifications

Therapeutic Classification: vascular headache suppressants

Pharmacologic Classification: five ht1 agonists

Indications

REMS

Action

Therapeutic Effects:

Pharmacokinetics

Absorption: Well absorbed (97%) after SUBQ administration. Absorption after oral administration is incomplete and significant amounts undergo substantial hepatic metabolism, resulting in poor bioavailability (14%). Well absorbed after intranasal administration.

Distribution: Well distributed to tissues.

Metabolism/Excretion: Mostly metabolized (80%) by the liver.

Half-life: 2 hr.

Time/Action Profile

(relief of migraine)

ROUTEONSETPEAKDURATION
POwithin 30 min2–4 hrup to 24 hr
SUBQ30 minup to 2 hrup to 24 hr
Nasalwithin 60 min2 hrunknown

Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Exercise Extreme Caution in:

Adv. Reactions/Side Effects

CV: angina, chest pressure, chest tightness, coronary vasospasm, ECG changes, MI, transient hypertension.

Derm: tingling, warm sensation, burning sensation, cool sensation, flushing.

EENT: alterations in vision, nasal sinus discomfort, throat discomfort.

GI: abdominal discomfort, dysphagia.

Local: injection site reaction.

MS: jaw discomfort, muscle cramps, myalgia, neck pain, neck stiffness.

Neuro: dizziness, vertigo, anxiety, drowsiness, fatigue, feeling of heaviness, feeling of tightness, headache, malaise, numbness, tight feeling in head, weakness.
Misc: (INCLUDING ANAPHYLAXIS AND ANGIOEDEMA)HYPERSENSITIVITY REACTIONS .

Interactions

Drug-Drug:

Drug-Natural Products:

Route/Dosage

Hepatic Impairment

Availability

(Generic available)

Assessment

Implementation

Patient/Family Teaching

Evaluation/Desired Outcomes

US Brand Names

Imitrex, Imitrex STATdose, Onzetra Xsail, Tosymra, Zembrace SymTouch

Canadian Brand Names

Imitrex DF